| Literature DB >> 32407190 |
Mi Liu1, Jie Ma1, Wei Jia1, Wanxiang Li1.
Abstract
We investigated the antibiotic-resistance phenotypes and molecularly characterized class 1 integron gene cassettes from 113 Pseudomonas aeruginosa isolates from patients. Primers specific for the class 1 integron integrase (intI1) gene were used to screen for these integrons using polymerase chain reactions (PCRs). The variable regions of the integrons were PCR-amplified and sequenced. Sputum was the most common specimen (69.9%; 79/113) followed by aseptic sites (21.2%; 24/113). Of the 113 isolates with phenotypic resistance to the tested antimicrobials, the highest resistances were to ciprofloxacin (CIP) (26.55%), imipenem (IPM) (23.89%), and meropenem (MEM) (23%). Carbapenem-sensitive P. aeruginosa (CS-PA) isolates displayed 23 patterns, and the predominant multidrug resistance phenotype was CIP-levofloxacin (7.23%, 6/83). Carbapenem-resistant P. aeruginosa (CR-PA) isolates displayed 12 patterns, and the predominant multidrug resistance phenotype was IPM-MEM (23.33%, 7/30). Class 1 integrons were detected in 14 (12.4%, 14/113) isolates, 7.22% (6/83) in CS-PA isolates, and 26.67% (8/30) in CR-PA isolates. Six gene cassette arrays were detected, the most prevalent being aacA4-blaOXA101-aadA5 in five isolates (4.4%, 5/113). Seventeen gene cassettes were detected. The most prevalent antibiotic-resistance gene cassettes were aacA4 (6.2%, 7/113), blaOXA-1, and blaOXA-101. Extended-spectrum β-lactamase resistance genes were detected. Some of the genes carried were similar to those in other species, but some had shared characteristics among the P. aeruginosa isolates. Long-standing drug resistance genes appeared to be under elimination in P. aeruginosa, whereas integrons conferring resistance to commonly used clinical drugs such as β-lactamases, fluoroquinolones, and even carbapenems, as well as some other gene elements, were found to be newly integrated.Entities:
Keywords: Pseudomonas aeruginosa; antibiotics resistance; class 1 integrons; molecular characterization
Mesh:
Substances:
Year: 2020 PMID: 32407190 PMCID: PMC7307683 DOI: 10.1089/mdr.2019.0406
Source DB: PubMed Journal: Microb Drug Resist ISSN: 1076-6294 Impact factor: 3.431
PCR Primers Used in This Study
| Gene | Description | Sequence (5′→3′) | Reference |
|---|---|---|---|
| Screening primer for class 1 integrons | CCAAGCTCTCGGGTAACATC | [ | |
| Screening primer for class 1 integrons | GCCCAGCTTCTGTATGGAAC | [ | |
| Screening primer for the variable region of class 1 integrons | GGCATCCAAGCAGCAAG | [ | |
| Screening primer for the variable region of class 1 integrons | AAGCAGACTTGACCTGA | [ |
Resistance Phenotypes and Comparison of Carbapenem-Resistant Pseudomonas aeruginosa with Carbapenem-Sensitive P. aeruginosa
| CR-PA | CS-PA | Total (%) | ||
|---|---|---|---|---|
| AK | 23.33 | 0 | 7.07 | 0.000 |
| ATM | 26.67 | 14.46 | 17.70 | 0.222 |
| CAZ | 36.67 | 3.61 | 12.39 | 0.000 |
| CIP | 53.33 | 15.66 | 26.55 | 0.000 |
| CSL | 36.67 | 6.02 | 15.04 | 0.000 |
| FEP | 36.67 | 0 | 9.73 | 0.000 |
| GEN | 16.67 | 6.02 | 9.73. | 0.079 |
| IPM | 93.33 | 0 | 23.89 | — |
| LEV | 56.67 | 16.87 | 27.4 | 0.000 |
| MEM | 86.67 | 0 | 23.0 | — |
| PIP | 36.67 | 13.25 | 19.46 | 0.006 |
| TOB | 30.00 | 4.81 | 12.39 | 0.001 |
| TZP | 30.00 | 6.02 | 12.39 | 0.001 |
AK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; CR-PA, carbapenem-resistant P. aeruginosa; CSL, cefoperazone/sulbactam; CS-PA, carbapenem-sensitive P. aeruginosa; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LEV, levofloxacin; MEM, meropenem; PRL, piperacillin; TOB, tobramycin; TZP, piperacillin/tazobactam.
Antimicrobial Resistance Phenotypes and Molecular Characterization of Gene Cassettes in Class 1 Integrons
| Sample no. | Resistance pattern | Int | Length | Gene cassettes | GenBank accession no. |
|---|---|---|---|---|---|
| 1, 2, 4, 8, 9, 15, 17, 20, 22, 26, 27, 29, 30, 31, 34, 38, 38, 44, 45, 47, 49, 50, 52, 53, 55, 56, 57, 60, 62, 63, 64, 65, 66, 67, 68, 69, 73, 74, 75, 76, 77, 78, 79, 80, 82, 84, 89, 93, 95, 96, 98, 102, 106, 107, 109, 110, 112, 114, 115, 116 | Sensitive to all drugs | − | − | − | |
| CS-PA | |||||
| 3, 83 | ATM | − | − | − | |
| 117 | PRL | − | − | − | |
| 25, 51, 92, 94, 99, 105 | CIP, LEV | − | − | − | |
| 85 | ATM, PRL | − | − | − | |
| 13 | LEV, PRL | − | − | − | |
| 41 | ATM, CIP, LEV | − | − | − | |
| 100 | ATM, CIP, LEV | + | − | − | |
| 43 | CAZ, PRL, TZP | − | − | − | |
| 5, 88 | CIP, LEV, IPM | − | − | − | |
| 61 | CIP, LEV, PRL | − | − | − | |
| 104 | CIP, LEV, GEN | + | − | − | |
| 35 | ATM, CSL, PRL | + | 1.1k | AadA22 | CP041394.1 |
| 23 | GEN, PRL, TOB, TZP | + | 2.1k | ||
| 32 | ATM, CSL, PRL, TZP | − | − | − | |
| 6, 11, 19 | CIP, LEV, IPM, MEM | − | − | ||
| 48 | ATM, CIP, LEV, MEM | − | − | − | |
| 16 | CSL, LEV, IPM, MEM | − | − | − | |
| 87 | ATM, CIP, GEN, LEV, TOB | − | − | − | |
| 108 | ATM, CAZ, CSL, PRL, TOB | − | − | − | |
| 18 | CAZ, CIP, FEP, GEN, LEV, TOB | + | − | − | |
| 111 | AK, ATM, CIP, CSL, GEN, TOB | + | 3.2k | ||
| 97 | ATM, CIP, CSL, GEN, LEV, PRL, TOB | − | − | ||
| 42 | ATM, CAZ, CIP, CSL, GEN, LEV, PRL, TOB, TZP | − | − | − | |
| CR-PA | |||||
| 21 | IPM, MEM, LEV | − | − | − | |
| 14 | IPM, MEM, PRL | − | − | − | |
| 7, 10, 12, 40, 59, 81, 113 | IPM, MEM | − | − | − | |
| 72 | CAZ, IPM, MEM, PRL | − | − | − | |
| 103 | CIP, FEP, LEV, IPM, MEM | − | − | − | |
| 28 | ATM, CAZ, CSL, FEP, IPM, MEM, PRL | − | − | − | |
| 33 | ATM, CAZ, CSL, IPM, MEM, PRL, TZP | − | − | − | |
| 54 | CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | − | − | |
| 71 | AK, ATM, CAZ, CIP, CSL, FEP, IPM, MEN, PRL, TOB, TZP | + | 2.1k | ||
| 36, 46, 101 | AK, ATM, CAZ, CIP, CSL, FEP, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.1k | ||
| 39, 70 | AK, CAZ, CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.2k+2.8k | ||
| 24 | AK, ATM, CAZ, CIP, CSL, FEP, GEN, IPM, LEV, MEN, PRL, TOB, TZP | + | 2.1k | ||
+, presence of the PCR product; −, absence of the PCR product.
ATM, aztreonam (30 mg); IPM, imipenem (10 mg).
FIG. 1.Genetic environment of class 1 integron variable regions. (A) Isolate 35. (B) Isolate 23. (C) Isolates 24, 36, 46, 71, and 101. (D1, D2) Isolates 39 and 70. (E) Isolate 111.
Comparison Between Integron-Positive and Integron-Negative Isolates
| int+ (%) | int− (%) | ||
|---|---|---|---|
| AK | 50.00 | 0.00 | 0.000 |
| ATM | 57.14 | 12.12 | 0.000 |
| CAZ | 57.14 | 6.06 | 0.000 |
| CIP | 78.57 | 18.18 | 0.000 |
| CSL | 64.29 | 7.07 | 0.000 |
| FEP | 64.29 | 2.02 | 0.000 |
| GEN | 50.00 | 3.03 | 0.000 |
| IPM | 57.14 | 20.20 | 0.003 |
| LEV | 71.43 | 21.21 | 0.000 |
| MEM | 57.14 | 18.18 | 0.001 |
| PIP | 64.29 | 13.13 | 0.000 |
| TOB | 71.43 | 3.03 | 0.000 |
| TZP | 64.29 | 5.05 | 0.000 |
int+: integron-positive isolates; int−: integron negative isolates.